The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

Matthew D. SeftelDepartment of Medical Oncology and Hematology, CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada; Correspondence[email protected]

John KuruvillaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada;

Tom KouroukisDepartment of Oncology, Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada;

Versha BanerjiDepartment of Medical Oncology and Hematology, CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada;

Graeme FraserDepartment of Oncology, Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada;

Michael CrumpDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada;

Rajat KumarDepartment of Medical Oncology and Hematology, CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada;

Haji I. ChalchalDepartment of Hematology, Allan Blair Cancer Centre, Regina, SK, Canada; ;University of Saskatchewan, Saskatchewan, SK, Canada;

Muhammad SalimDepartment of Hematology, Allan Blair Cancer Centre, Regina, SK, Canada; ;University of Saskatchewan, Saskatchewan, SK, Canada;

Rob C. LaisterDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada;

Susan CrockerDepartment of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada;

Spencer B. GibsonResearch Institute of Oncology and Hematology, CancerCare Manitoba and Department of Biochemistry, University of Manitoba, Winnipeg, MB, Canada;

Marcia ToguchiAstex Pharmaceuticals, Cambridge, UK;

John F. LyonsAstex Pharmaceuticals, Cambridge, UK;

Hao XuCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;

Jean PowersCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;

Joana SederiasCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;

Lesley SeymourCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;

Annette E. HayCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada; ;Department of Medicine, Queen’s University, Kingston, ON, Canada

show all

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date